Second medical use: a regulatory perspective

As compound patents and regulatory data protection for medicinal products expire, pharmaceutical companies increasingly look to develop new uses for their products. This strategy usually involves filing second medical use patents to protect the invention and research investment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

5 February 2026 Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.

Europe

Drowning in EU regulations? Five tips for surviving the deluge of new rules

3 February 2026 As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

More features

Semaglutide patent battle heats up with new blow for Novo in India

Wilson Sonsini senior counsel moves to a rival firm

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Moderna VP and regulatory expert moves to private practice

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Sanofi suffers setback in insulin monopoly dispute

Second medical use: a regulatory perspective

More on this story

Editor's picks

Editor's picks

More features